MEDICA SCIENTIA INNOVATION RESEARCH SL, has received financial support from IVACE through the HORIZONTE-CV Program and financial support from the European Union for having been selected in the framework of the ERDF Operational Program of the Valencian Region 2014-2020 with file number IMAPEA/2018/41 for the presentation of the RANDOMIZED, DOUBLE-BLIND PHASE II STUDY TO EVALUATE THE POTENTIAL OF HERICIUM ERINACEUS IN PREVENTING AND MANAGING ACUTE AND LONG-TERM CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY (CIPN) IN CHEMOTHERAPY (HECTOR) project to the “Horizon 2020” program.
Comments